Alumis Inc. (ALMS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.68: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 11.28; Below-average business quality.
Alumis is a clinical-stage biopharmaceutical company developing TYK2 inhibitors: envu (envudeucitinib), a second-generation allosteric inhibitor with positive Phase 3 data in plaque psoriasis (Jan 2026) and Phase 2b ongoing in SLE, plus A-005, a CNS-penetrant TYK2 inhibitor in... Read more
Sell if holding. Engine safety override at $18.68: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 11.28; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 64d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Alumis Inc.
Latest news
- NEWS Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40 — benzinga May 19, 2026 positive
- NEWS This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday — benzinga May 15, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Alumis, Raises Price Target to $51 — benzinga May 15, 2026 positive
- NEWS Guggenheim Maintains Buy on Alumis, Raises Price Target to $34 — benzinga May 15, 2026 positive
- NEWS This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday — benzinga May 15, 2026 negative
Generated 2026-06-09T22:11:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineenvu10-K Item 1A: 'Our ability to achieve profitability in the future is dependent upon obtaining regulatory approval for and successfully commercializing our most advanced candidate, envu'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Volatile — 5.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.68: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 11.28; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $17.95. Score 4.9/10, moderate confidence.
Take-profit target: $34.89 (+87.0% upside). Prior stop was $17.95. Stop-loss: $17.95.
Concentration risk — Pipeline: envu; Quality below floor (2.9 < 4.0).
Alumis Inc. trades at a P/E of N/A (forward -6.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover ALMS with a consensus score of 4.4/5. Average price target: $40.
What does Alumis Inc. do?Alumis is a clinical-stage biopharmaceutical company developing TYK2 inhibitors: envu (envudeucitinib), a...
Alumis is a clinical-stage biopharmaceutical company developing TYK2 inhibitors: envu (envudeucitinib), a second-generation allosteric inhibitor with positive Phase 3 data in plaque psoriasis (Jan 2026) and Phase 2b ongoing in SLE, plus A-005, a CNS-penetrant TYK2 inhibitor in Phase 1. The company has no approved products and no revenue.